
ALT Decompensated cirrhosis is not always permanent: curing or controlling the underlying cause can return patients to a compensated state, especially when disease is less severe and treatment starts early. This review defines recompensation, summarizes its natural history and clinical implications, and outlines considerations for clinical trials.

ALT Two figures showing the effect of retatrutide on body weight. Panel A shows the percent change in body weight from baseline to week 80 (controlled for type I error). Panel B shows the percentage of patients with reductions in body weight of 15% or more and 30% or more (controlled for type I error), along with the percentage of patients who reached the body-mass index targets of less than 30 or less than 25 and the waist-to-height ratio target of less than 0.5 (not controlled for type I error) at week 80 for the treatment-regimen estimand.




































